Immunotech Laboratories (IMMB) Osake Kurssi

Immunotech Laboratories Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Immunotech Laboratories Inc in the market include companies such as Johnson & Johnson, GlaxoSmithKline, Pfizer, and Merck & Co.

Immunotech Laboratories Inc is a biopharmaceutical company specializing in the development and commercialization of immunotherapy products for the treatment of HIV/AIDS and cancer. Established in 2007, the company has since focused on researching and advancing its flagship product, Immunotherapy V5, which aims to boost the body's immune system to fight against these diseases. With a focus on innovative and cutting-edge therapies, Immunotech Laboratories Inc has gained recognition in the healthcare industry. By continuously investing in scientific advancements and clinical trials, the company strives to provide breakthrough treatments that can improve the quality of life for patients worldwide.

Immunotech Laboratories Inc has achieved several significant milestones. The company successfully developed the unique technology, LDN (Low Dose Naltrexone), which has shown promising results in treating HIV/AIDS. Furthermore, Immunotech Laboratories Inc has conducted clinical trials for their LDN therapy, demonstrating its potential in reducing viral load and increasing CD4 count in patients. The company has also received FDA approval for IND application, allowing them to continue their research and development efforts. Immunotech Laboratories Inc's advancements in LDN treatment have positioned them as a leading player in the field of immunotherapy for HIV/AIDS.

Immunotech Laboratories Inc is primarily present in the United States of America (USA).

Immunotech Laboratories Inc represents core values of innovation, dedication, and patient-centricity. With a commitment to developing advanced therapeutic solutions, Immunotech aims to improve patients' quality of life. The company's corporate philosophy revolves around providing cutting-edge medical technologies that address unmet medical needs, paving the way for breakthrough treatments. Immunotech Laboratories Inc strives to prioritize patient well-being, harnessing advanced scientific research to develop effective immunotherapies. By placing patients at the center of their endeavors, Immunotech exemplifies their dedication to solving critical health challenges and improving global healthcare outcomes.

Nykyisellä valuuttakurssilla Immunotech Laboratories-osake noteerataan hintaan 0,00 EUR (0,00 USD).

Immunotech Laboratories Inc. is a company in the biotechnology industry that specializes in the development and marketing of immunotherapies for the treatment of chronic and severe diseases. The company's business model is based on innovative technologies and research findings that enable it to develop effective and safe products that improve the health and well-being of patients around the world.

Liikevaihtoa ei voida laskea Immunotech Laboratories:lle tällä hetkellä.

Voittoa ei voida laskea Immunotech Laboratories:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Immunotech Laboratories:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Immunotech Laboratories:lle tällä hetkellä.

Immunotech Laboratories:n Eulpool-laatuscore on 2/10.

Immunotech Laboratories:n ISIN on US45254F2039. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Immunotech Laboratories:n WKN on A0RF8Y. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Immunotech Laboratories:n ticker on IMMB. Tämä pörssinoteeraus käytetään Immunotech Laboratories-osakkeiden kauppaan pörssissä.